# Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

> **NCT05423691** · PHASE1 · RECRUITING · sponsor: **Cellenkos, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** CK0804

## Key facts

- **NCT ID:** NCT05423691
- **Lead sponsor:** Cellenkos, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-27
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05423691

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05423691, "Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05423691. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*